Forward of oral arguments on entry to remedy abortion earlier than the Supreme Court docket on March 26, KFF examines how a Court docket ruling would restrict plaintiffs' entry to mifepristone, limiting its use in telehealth and distribution via pharmacies blocked, together with in states the place abortion is authorized and guarded. Moreover, it might doubtlessly weaken the position of the Meals and Drug Administration (FDA) in reviewing medicine – one thing the Court docket has by no means carried out earlier than.

As a part of the reason, KFF describes the problems at stake within the final result of Alliance for Hippocratic Drugs (AHM) vs. Meals and Drug Administration (FDA)And Danco Laboratories LLC v. AHM, and examines the decrease court docket rulings that led to the Supreme Court docket taking over the case, and the authorized standing of the plaintiffs, who’re anti-abortion organizations and docs – and their claims. With remedy abortion accounting for practically two-thirds of abortions within the U.S. and 16% of all abortions now occurring through telehealth, with abortion tablets shipped to the affected person, the result of the case might finish entry to remedy abortion throughout the nation. nation can restrict.

KFF additionally explores the doubtless far-reaching implications for the Court docket's ruling on the FDA's authority to proceed regulating a variety of medicine, together with medicine which may be thought of controversial immediately and sooner or later.

Further KFF sources on remedy abortion in america embrace: